MedTrace Logo

A Study of ABT-652 in Adults With Osteoarthritis Pain of the Knee

NCT01207115 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 322

Last updated 2013-01-07

No results posted yet for this study

Summary

To compare the analgesic efficacy and safety of ABT-652 administered twice daily (BID) to placebo in subjects with osteoarthritis (OA) of the knee.

Conditions

  • Osteoarthritis of the Knee

Interventions

DRUG

ABT-652

ABT-652 capsules - twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm

DRUG

Placebo

Placebo capsules - twice daily for 8 weeks

DRUG

Naproxen

Naproxen capsules - twice daily for 8 weeks

Sponsors & Collaborators

  • AbbVie (prior sponsor, Abbott)

    lead INDUSTRY

Principal Investigators

  • Rachel Duan, MD · AbbVie

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-05-31
Completion
2011-05-31

Countries

  • United States
  • Australia
  • Canada
  • Chile
  • Puerto Rico

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01207115 on ClinicalTrials.gov